Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
TARACTAN is an oral tablet small molecule approved by Roche in 1962 for an undisclosed indication. The specific mechanism of action and therapeutic area are not documented in available data.
Product approaching loss of exclusivity with minimal current commercial visibility; team likely focused on lifecycle extension or managed decline.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
TARACTAN currently generates zero linked job openings, indicating a small or wind-down team. Career mobility may be limited unless you seek roles in lifecycle management, competitive positioning, or portfolio rebalancing.
Worked on TARACTAN at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.